{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:56:50Z","timestamp":1785495410963,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1101403"],"award-info":[{"award-number":["2021YFA1101403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82090043"],"award-info":[{"award-number":["82090043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81825008"],"award-info":[{"award-number":["81825008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pilot Project for Public Welfare Development and Reform of Beijing-affiliated Medical Research Institutes","award":["Beijing Medical Research 2021-8"],"award-info":[{"award-number":["Beijing Medical Research 2021-8"]}]},{"name":"Project of Construction and Support for high-level Innovative Teams of Beijing Municipal Institutions","award":["BPHR20220112"],"award-info":[{"award-number":["BPHR20220112"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732407"],"award-info":[{"award-number":["2023M732407"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005024","name":"Beijing Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023-ZZ-004"],"award-info":[{"award-number":["2023-ZZ-004"]}],"id":[{"id":"10.13039\/501100005024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Beijing Scholar","award":["NO.020"],"award-info":[{"award-number":["NO.020"]}]},{"name":"Dengfeng Talent Program","award":["DFL20220701"],"award-info":[{"award-number":["DFL20220701"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating muscle weakness. Despite the availability of established therapies, the management of MG symptoms remains suboptimal, partially attributed to lack of efficacy or intolerable side-effects. Therefore, new effective drugs are warranted for treatment of MG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>By employing an analytical framework that combines Mendelian randomization (MR) and colocalization analysis, we estimate the causal effects of blood druggable expression quantitative trait loci (eQTLs) and protein quantitative trait loci (pQTLs) on the susceptibility of MG. We subsequently investigated whether potential genetic effects exhibit cell-type specificity by utilizing genetic colocalization analysis to assess the interplay between immune-cell-specific eQTLs and MG risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified significant MR results for four genes (<jats:italic>CDC42BPB, CD226, PRSS36, and TNFSF12<\/jats:italic>) using <jats:italic>cis-<\/jats:italic>eQTL genetic instruments and three proteins (CTSH, PRSS8, and CPN2) using <jats:italic>cis-<\/jats:italic>pQTL genetic instruments. Six of these loci demonstrated evidence of colocalization with MG susceptibility (posterior probability\u2009&gt;\u20090.80). We next undertook genetic colocalization to investigate cell-type-specific effects at these loci. Notably, we identified robust evidence of colocalization, with a posterior probability of 0.854, linking CTSH expression in T<jats:sub>H<\/jats:sub>2 cells and MG risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study provides crucial insights into the genetic and molecular factors associated with MG susceptibility, singling out CTSH as a potential candidate for in-depth investigation and clinical consideration. It additionally sheds light on the immune-cell regulatory mechanisms related to the disease. However, further research is imperative to validate these targets and evaluate their feasibility for drug development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-024-04994-2","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T04:19:58Z","timestamp":1711253998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilai","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-5434","authenticated-orcid":false,"given":"Junwei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,24]]},"reference":[{"issue":"1","key":"4994_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4994_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176\u201388. https:\/\/doi.org\/10.1016\/s1474-4422(21)00297-0.","journal-title":"Lancet Neurol"},{"issue":"7","key":"4994_CR3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acn3.51792","volume":"10","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang F, Long Z, et al. Mortality of myasthenia gravis: a national population-based study in China. Ann Clin Transl Neurol. 2023;10(7):1095\u2013105. https:\/\/doi.org\/10.1002\/acn3.51792.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"4994_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13023-019-1025-5","volume":"14","author":"J Finsterer","year":"2019","unstructured":"Finsterer J. Congenital myasthenic syndromes. Orphanet J Rare Dis. 2019;14(1):57. https:\/\/doi.org\/10.1186\/s13023-019-1025-5.","journal-title":"Orphanet J Rare Dis"},{"key":"4994_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jaut.2013.12.001","volume":"52","author":"N Avidan","year":"2014","unstructured":"Avidan N, Le Panse R, Berrih-Aknin S, et al. Genetic basis of myasthenia gravis - a comprehensive review. J Autoimmun. 2014;52:146\u201353. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.001.","journal-title":"J Autoimmun"},{"issue":"2","key":"4994_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1375\/twin.14.2.129","volume":"14","author":"R Ramanujam","year":"2011","unstructured":"Ramanujam R, Pirskanen R, Ramanujam S, et al. Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res Hum Genet. 2011;14(2):129\u201336. https:\/\/doi.org\/10.1375\/twin.14.2.129.","journal-title":"Twin Res Hum Genet"},{"issue":"9","key":"4994_CR7","doi-asserted-by":"publisher","first-page":"102349","DOI":"10.1016\/j.autrev.2019.102349","volume":"18","author":"H Zhong","year":"2019","unstructured":"Zhong H, Zhao C, Luo S. HLA in myasthenia gravis: from superficial correlation to underlying mechanism. Autoimmun Rev. 2019;18(9):102349. https:\/\/doi.org\/10.1016\/j.autrev.2019.102349.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"4994_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","volume":"72","author":"AE Renton","year":"2015","unstructured":"Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396\u2013404. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4103.","journal-title":"JAMA Neurol"},{"key":"4994_CR9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108672119","author":"R Chia","year":"2022","unstructured":"Chia R, Saez-Atienzar S, Murphy N, et al. Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022. https:\/\/doi.org\/10.1073\/pnas.2108672119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4994_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00916-w","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024. https:\/\/doi.org\/10.1038\/s41582-023-00916-w.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"4994_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren JJ, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189\u2013202. https:\/\/doi.org\/10.1016\/s1474-4422(21)00463-4.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4994_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/wnl.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 Update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/wnl.0000000000011124.","journal-title":"Neurology"},{"issue":"10","key":"4994_CR13","doi-asserted-by":"publisher","first-page":"100190","DOI":"10.1016\/j.xgen.2022.100190","volume":"2","author":"S Namba","year":"2022","unstructured":"Namba S, Konuma T, Wu KH, et al. A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genom. 2022;2(10):100190. https:\/\/doi.org\/10.1016\/j.xgen.2022.100190.","journal-title":"Cell Genom"},{"issue":"1","key":"4994_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.tig.2022.08.005","volume":"39","author":"P Kreitmaier","year":"2023","unstructured":"Kreitmaier P, Katsoula G, Zeggini E. Insights from multi-omics integration in complex disease primary tissues. Trends in genetics\u202f: TIG. 2023;39(1):46\u201358. https:\/\/doi.org\/10.1016\/j.tig.2022.08.005.","journal-title":"Trends in genetics : TIG"},{"issue":"9","key":"4994_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/014107680710000923","volume":"100","author":"SG Davey","year":"2007","unstructured":"Davey SG. Capitalizing on Mendelian randomization to assess the effects of treatments. J R Soc Med. 2007;100(9):432\u20135. https:\/\/doi.org\/10.1177\/014107680710000923.","journal-title":"J R Soc Med"},{"issue":"9","key":"4994_CR16","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa U, Claringbould A, Westra H-J, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300\u201310. https:\/\/doi.org\/10.1038\/s41588-021-00913-z.","journal-title":"Nat Genet"},{"issue":"5","key":"4994_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41588-022-01051-w","volume":"54","author":"J Zhang","year":"2022","unstructured":"Zhang J, Dutta D, K\u00f6ttgen A, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022;54(5):593\u2013602. https:\/\/doi.org\/10.1038\/s41588-022-01051-w.","journal-title":"Nat Genet"},{"issue":"7708","key":"4994_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0175-2.","journal-title":"Nature"},{"key":"4994_CR19","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1038\/ncomms14357","volume":"8","author":"K Suhre","year":"2017","unstructured":"Suhre K, Arnold M, Bhagwat AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017;8:14357. https:\/\/doi.org\/10.1038\/ncomms14357.","journal-title":"Nat Commun"},{"issue":"4","key":"4994_CR20","doi-asserted-by":"publisher","first-page":"e1006706","DOI":"10.1371\/journal.pgen.1006706","volume":"13","author":"L Folkersen","year":"2017","unstructured":"Folkersen L, Fauman E, Sabater-Lleal M, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 2017;13(4):e1006706. https:\/\/doi.org\/10.1371\/journal.pgen.1006706.","journal-title":"PLoS Genet"},{"issue":"6404","key":"4994_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1126\/science.aaq1327","volume":"361","author":"V Emilsson","year":"2018","unstructured":"Emilsson V, Ilkov M, Lamb JR, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769\u201373. https:\/\/doi.org\/10.1126\/science.aaq1327.","journal-title":"Science"},{"issue":"1","key":"4994_CR22","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41467-018-05512-x","volume":"9","author":"C Yao","year":"2018","unstructured":"Yao C, Chen G, Song C, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 2018;9(1):3268. https:\/\/doi.org\/10.1038\/s41467-018-05512-x.","journal-title":"Nat Commun"},{"key":"4994_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, et al. The druggable genome and support for target identification and validation in drug development. Sci Trans Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aag1166.","journal-title":"Sci Trans Med"},{"issue":"10","key":"4994_CR24","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","volume":"52","author":"J Zheng","year":"2020","unstructured":"Zheng J, Haberland V, Baird D, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020;52(10):1122\u201331. https:\/\/doi.org\/10.1038\/s41588-020-0682-6.","journal-title":"Nat Genet"},{"issue":"6","key":"4994_CR25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","volume":"175","author":"BJ Schmiedel","year":"2018","unstructured":"Schmiedel BJ, Singh D, Madrigal A, et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell. 2018;175(6):1701-15.e16. https:\/\/doi.org\/10.1016\/j.cell.2018.10.022.","journal-title":"Cell"},{"issue":"20","key":"4994_CR26","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/bioinformatics\/btw373","volume":"32","author":"JR Staley","year":"2016","unstructured":"Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics. 2016;32(20):3207\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btw373.","journal-title":"Bioinformatics"},{"issue":"11","key":"4994_CR27","doi-asserted-by":"publisher","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey SG. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081. https:\/\/doi.org\/10.1371\/journal.pgen.1007081.","journal-title":"PLoS Genet"},{"issue":"4","key":"4994_CR28","doi-asserted-by":"publisher","first-page":"e1008720","DOI":"10.1371\/journal.pgen.1008720","volume":"16","author":"C Wallace","year":"2020","unstructured":"Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16(4):e1008720. https:\/\/doi.org\/10.1371\/journal.pgen.1008720.","journal-title":"PLoS Genet"},{"issue":"5","key":"4994_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41588-019-0404-0","volume":"51","author":"B Liu","year":"2019","unstructured":"Liu B, Gloudemans MJ, Rao AS, et al. Abundant associations with gene expression complicate GWAS follow-up. Nat Genet. 2019;51(5):768\u20139. https:\/\/doi.org\/10.1038\/s41588-019-0404-0.","journal-title":"Nat Genet"},{"issue":"2","key":"4994_CR30","doi-asserted-by":"publisher","first-page":"e1003270","DOI":"10.1371\/journal.pgen.1003270","volume":"9","author":"J Faraco","year":"2013","unstructured":"Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 2013;9(2):e1003270. https:\/\/doi.org\/10.1371\/journal.pgen.1003270.","journal-title":"PLoS Genet"},{"issue":"2","key":"4994_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nri.2017.118","volume":"18","author":"JA Walker","year":"2018","unstructured":"Walker JA, McKenzie ANJ. T(H)2 cell development and function. Nat Rev Immunol. 2018;18(2):121\u201333. https:\/\/doi.org\/10.1038\/nri.2017.118.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"4994_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41573-022-00561-w","volume":"22","author":"KJ Carss","year":"2023","unstructured":"Carss KJ, Deaton AM, Del Rio-Espinola A, et al. Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discovery. 2023;22(2):145\u201362. https:\/\/doi.org\/10.1038\/s41573-022-00561-w.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"4994_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/d41573-021-00023-9","volume":"20","author":"MP East","year":"2021","unstructured":"East MP, Asquith CRM. CDC42BPA\/MRCK\u03b1: a kinase target for brain, ovarian and skin cancers. Nat Rev Drug Discov. 2021;20(3):167. https:\/\/doi.org\/10.1038\/d41573-021-00023-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"50","key":"4994_CR34","doi-asserted-by":"publisher","first-page":"E11731","DOI":"10.1073\/pnas.1814052115","volume":"115","author":"X Du","year":"2018","unstructured":"Du X, de Almeida P, Manieri N, et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc Natl Acad Sci U S A. 2018;115(50):E11731\u201340. https:\/\/doi.org\/10.1073\/pnas.1814052115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"4994_CR35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41423-020-00633-0","volume":"19","author":"J Bi","year":"2022","unstructured":"Bi J. CD226: a potent driver of antitumor immunity that needs to be maintained. Cell Mol Immunol. 2022;19(9):969\u201370. https:\/\/doi.org\/10.1038\/s41423-020-00633-0.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"4994_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.immuni.2020.09.006","volume":"53","author":"M Weulersse","year":"2020","unstructured":"Weulersse M, Asrir A, Pichler AC, et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity. 2020;53(4):824-39.e10. https:\/\/doi.org\/10.1016\/j.immuni.2020.09.006.","journal-title":"Immunity"},{"issue":"Pt 11","key":"4994_CR37","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1093\/brain\/awv256","volume":"138","author":"M Pi\u00e9davent-Salomon","year":"2015","unstructured":"Pi\u00e9davent-Salomon M, Willing A, Engler JB, et al. Multiple sclerosis associated genetic variants of CD226 impair regulatory T cell function. Brain. 2015;138(Pt 11):3263\u201374. https:\/\/doi.org\/10.1093\/brain\/awv256.","journal-title":"Brain"},{"issue":"28","key":"4994_CR38","doi-asserted-by":"publisher","first-page":"10305","DOI":"10.1073\/pnas.1402571111","volume":"111","author":"T Fl\u00f8yel","year":"2014","unstructured":"Fl\u00f8yel T, Brorsson C, Nielsen LB, et al. CTSH regulates \u03b2-cell function and disease progression in newly diagnosed type 1 diabetes patients. Proc Natl Acad Sci U S A. 2014;111(28):10305\u201310. https:\/\/doi.org\/10.1073\/pnas.1402571111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4994_CR39","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/s41467-023-36120-z","volume":"14","author":"HM Ollila","year":"2023","unstructured":"Ollila HM, Sharon E, Lin L, et al. Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. Nat Commun. 2023;14(1):2709. https:\/\/doi.org\/10.1038\/s41467-023-36120-z.","journal-title":"Nat Commun"},{"issue":"4","key":"4994_CR40","first-page":"471","volume":"9","author":"JO Link","year":"2006","unstructured":"Link JO, Zipfel S. Advances in cathepsin S inhibitor design. Curr Opin Drug Discov Devel. 2006;9(4):471\u201382.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"5","key":"4994_CR41","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jth.13964","volume":"16","author":"J Morser","year":"2018","unstructured":"Morser J, Shao Z, Nishimura T, et al. Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice. J Thromb Haemost. 2018;16(5):991\u20131002. https:\/\/doi.org\/10.1111\/jth.13964.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"4994_CR42","doi-asserted-by":"publisher","first-page":"e000241","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1):e000241. https:\/\/doi.org\/10.1136\/bmjmed-2022-000241.","journal-title":"BMJ Med"},{"issue":"4","key":"4994_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00535-019-01660-z","volume":"55","author":"Y Sugitani","year":"2020","unstructured":"Sugitani Y, Nishida A, Inatomi O, et al. Sodium absorption stimulator prostasin (PRSS8) has an anti-inflammatory effect via downregulation of TLR4 signaling in inflammatory bowel disease. J Gastroenterol. 2020;55(4):408\u201317. https:\/\/doi.org\/10.1007\/s00535-019-01660-z.","journal-title":"J Gastroenterol"},{"issue":"6589","key":"4994_CR44","doi-asserted-by":"publisher","first-page":"eabf3041","DOI":"10.1126\/science.abf3041","volume":"376","author":"S Yazar","year":"2022","unstructured":"Yazar S, Alquicira-Hernandez J, Wing K, et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science. 2022;376(6589):eabf3041. https:\/\/doi.org\/10.1126\/science.abf3041.","journal-title":"Science"},{"issue":"7","key":"4994_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-022-00802-7","volume":"18","author":"S Onuora","year":"2022","unstructured":"Onuora S. Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells. Nat Rev Rheumatol. 2022;18(7):363. https:\/\/doi.org\/10.1038\/s41584-022-00802-7.","journal-title":"Nat Rev Rheumatol"},{"issue":"36","key":"4994_CR46","doi-asserted-by":"publisher","first-page":"e2209096119","DOI":"10.1073\/pnas.2209096119","volume":"119","author":"R Chia","year":"2022","unstructured":"Chia R, Saez-Atienzar S, Drachman DB, et al. Implications of CHRNB1 and ERBB2 in the pathobiology of myasthenia gravis. Proc Natl Acad Sci U S A. 2022;119(36):e2209096119. https:\/\/doi.org\/10.1073\/pnas.2209096119.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-04994-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T04:20:15Z","timestamp":1711254015000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-04994-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4994"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-04994-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,24]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is covered under the Xuanwu Hospital, Capital Medical University, Human Research Ethics Committee approval ([2022]-148).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}